Optimi Health Begins 2026 Shipments of MDMA and Psilocybin Capsules to Australia
I'm LongbridgeAI, I can summarize articles.Optimi Health has completed its first production cycle of MDMA and psilocybin capsules for Australia, packaging 1,000 capsules each. The capsules are approved for import under Australia’s Authorised Prescriber Scheme, addressing significant medical needs for PTSD and treatment-resistant depression. Analysts rate TSE:OPTI stock as a Hold with a C$0.50 price target, while Spark's AI Analyst gives it a Neutral score due to financial performance concerns. Optimi Health specializes in psychedelic treatments and operates GMP-compliant facilities in British Columbia.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Optimi Health ( (TSE:OPTI) ) has provided an update.
Optimi Health has completed its first 2026 production cycle of MDMA and psilocybin capsules for the Australian market, with 1,000 MDMA capsules (60 mg) and 1,000 naturally derived psilocybin capsules (5 mg) now fully packaged, labeled and batch-released under its Health Canada Drug Establishment Licence. Following issuance of Australian import permits, the GMP-compliant capsules have been approved for import under Australia’s Authorised Prescriber Scheme, positioning Optimi to continue and potentially expand supply into the country’s regulated healthcare system at a time when PTSD and treatment-resistant depression remain significant unmet medical needs affecting millions of Australians.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Spark’s Take on TSE:OPTI Stock
According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.
Optimi Health’s overall score is primarily impacted by its financial performance, which shows potential but is hindered by persistent losses and cash flow challenges. Technical analysis provides some positive momentum signals, but valuation concerns due to negative earnings weigh heavily on the score.
To see Spark’s full report on TSE:OPTI stock, click here.
More about Optimi Health
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer specializing in prescribed psychedelic treatments for mental health therapies, including validated MDMA and botanical psilocybin products. Operating from two 10,000-square-foot facilities in British Columbia, the company supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products available for prescription use in Australia under the Authorised Prescriber Scheme and accessible in Canada via the Special Access Program.
Average Trading Volume: 72,927
Technical Sentiment Signal: Buy
Current Market Cap: C$31.89M
Find detailed analytics on OPTI stock on TipRanks’ Stock Analysis page.